Ratings for Arcus Biosciences (NYSE:RCUS) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. In the assessment of 12-month price targets, analysts unveil insights for Arcus Biosciences, presenting an average target of $27.0, a high estimate of $30.00, and a low estimate of $23.00. Experiencing a 9.24% decline, the current average is now lower than the previous average price …